INTRODUCTION
Posttransplantation lymphoproliferative disorder (PTLD) is a serious complication
following solid organ transplantation. Most of PTLD is related to an interaction of
Epstein-Barr virus (EBV) infection and immune suppression.1,2 PTLD occurs most common
after intestine transplantation and the least common after renal transplantation.3,4
PTLD can involve any organs. Abdominal organs are frequently involved, and up to 50%
of all cases of PTLD are confined to the abdomen.5 The disease manifestation and the
anatomic pattern of organ involvement is highly dependent on the type of transplantation.
To provide more detailed understanding of hepatic involvement of PTLD, here a case
of PTLD involving liver after renal transplantation is presented with radiological
imaging findings. A review about classification and clinical considerations and the
imaging features of PTLD involving liver will be discussed. Familiarity with the imaging
findings of this disorder can help early and accurate diagnosis and result in better
prognosis.
CASE SUMMARY
A 17-year-old male was admitted with the complaint of generalized abdominal pain.
He had history of end stage renal disease due to focal segmental glomerulosclerosis.
He got kidney transplantation 6 years ago. Kidney donor was his mother. He had also
history of acute rejection immediately after kidney transplantation, and managed with
plasmapheresis and immunosuppresion. He was managed with drugs including Tacrolimus
(Prograf®, Astellas, Tokyo, Japan), mycophenolate mofetil (Cellcept®, Roche, Basel,
Switzerland), and Deflazacort (Calcort®, Sanofi-aventis, Paris, France) for six years
with gradual dose reduction.
He complained generalized abdominal pain for three days, and visited hospital. He
presented symptoms such as fever and night sweating, but no weight loss, dizziness,
dyspnea, anorexia, nausea, vomiting, diarrhea or other abdominal symptoms were presented.
He presented physical examination findings including hepatomegaly with three finger
width and mild abdominal distension.
The laboratory findings showed hemoglobin 8.5 g/dL, white blood cell count 8,500/mm3,
(neutrophil 63.2%, lymphocyte 22.1%), platelet count 284,000/mm3. Biochemical tests
showed that the serum level of alanine aminotransferase was 24 IU/L, aspartate aminotransferase
was 45 IU/L, and alkaline phosphatase was 99 IU/L. Serum protein was 5.7 g/dL and
albumin was 2.9 g/dL. Total bilirubin was 0.5 mg/dL. Blood urea nitrogen (BUN) was
20 mg/dL and creatinine was 1.3 mg/dL. Serum amylase was elevated as 590 U/L, but
lipase was 22 U/L. Lactate dehydrogenase was 1,612 IU/L and β-2 Microglobulin was
elevated to 6.6 µg/mL. Alpha-fetoprotein was less than 1 ng/mL. Hepatitis B surface
(HBs) antigen and anti-HBs were negative.
Contrast-enhanced abdomen CT was taken. There were multiple, well-defined, homogenously
low attenuated round masses in liver (Fig. 1A and B). Mass size was up to 2.5 cm.
Also there were multiple mesenteric mass over 10 cm (Fig. 1C and D). It showed heterogenous
enhancement and partial central necrotic low attenuation area. The mesenteric mass
showed encasement of mesenteric vessels and thickening of adjacent bowel wall. Ultrasonography
showed multiple well-defined homogenous low echoic masses in liver (Fig. 2).
Fludexoyglucose positron emission tomography (FDG-PET) scan showed multiple hypermetabolic
lesions in supraclavicular area, mediastinal area, liver, mesentery, peritoneum, and
multiple bones (Fig. 3).
Percutaneous fine-needle-aspiration biopsy was performed in right lobe mass under
ultrasound guidance. Histologic examination of the biopsy specimen showed post transplantation
lymphoprolifertive disease, monomorphic type (diffuse large B cell lymphoma). Special
staining results were as follows: CD20 (+), CD10 (+), bcl-6 (+), CD3 (-), CD5 (-),
CD56 (-), CD1a (-), TdT (-), EBV (-). Ki-67 labeling index was 60%.
After pathological diagnosis was confirmed, administration of mycophenolate mofetil
discontinued and, R-CHOP chemotherapy started. After three months with chemotherapy
of four cycles, follow up CT scan was taken. CT scan showed markedly decreased mass
in liver and mesentery (Fig. 4A-C). He is alive until now without recurrence after
30 months follow up.
DISCUSSION
PTLD is known as a serious complication of solid organ transplantation following with
immunosuppression. Development of lymphoma after transplantation was first described
by Doak et al6 in a renal transplant recipient in 1968, whereas the term post-transplant
lymphoproliferative disorder or disease was introduced by Starzl et al in 1984.7
An important risk factor for PTLD development is the intensity and the amount of immunosuppression
administered to the patient.1 Another risk factor is EBV-seronegative patients receiving
allografts from EBV-seropositive donors, consequently leading to primary EBV infection.
This is also the main reason for the higher incidences of PTLD observed in pediatric
transplant recipients.1 PTLD are related to infection from EBV, but the presence of
this virus is not essential for the diagnosis. EBV-negative PTLD is also recognized
as in this case presented above. This type of PTLD tends to develop much later after
transplantation and has a significantly worse outcome when compared with EBV-positive
PTLD.1,2
Society of Hematology and the World Health Organization generated the current classification
system, which identifies four major categories: 1) hyperplastic (or early) lesions;
2) polymorphic (generally monoclonal) lesions; 3) monomorphic (ie, lymphomatous invariably
monoclonal) lesions, which are further subcategorized along recognized lines of B-cell,
T-cell, or natural killer cell neoplasia; and 4) other lymphoproliferative disorders,
including Hodgkin lymphoma.8
Most cases develop PTLD within 1 year after the transplantation, although some cases
develop several years later. PTLD occurs in up to 5% of transplantation recipient
patients, depending on the type of organ transplanted and the type and duration of
immunosuppressive treatment.5 Allograft involvement by PTLD was more frequent in lung
and liver transplant recipients that in kidney and heart transplantation.3 The incidence
varies with allograft type, with reported frequencies following transplant of intestines
up to 20%, heart 2-10%, lung 4-8% liver 2-8% and kidneys 1%.4 However, as many thousands
of renal transplants are performed each year, the majority of PTLD are observed in
kidney transplant recipients.1 The abdominal cavity is frequently involved by PTLD,
with abdominal disease being seen in 50-75% of patients with PTLD.3,9 Extranodal involvement
(80% of cases) is more common than nodal involvement (20%) in intraabdominal disease.3
Liver is the most frequently involved abdominal solid organ, with involvement seen
in 30-45% of post-liver transplantation PTLD, 40% of post-pancreas transplantation
PTLD, 23% of post-heart transplantation PTLD and 10% of post-lung transplantation
PTLD.9 In another large collaborative study, liver involvement was seen in 22%, 9%,
5%, and 5% of cases of monomorphic PTLD (non-Hodgkin lymphoma) following liver, heart,
lung or lung-heart, and kidney transplantation, respectively.10
Imaging findings of PTLD have much in common with those of lymphoma. Especially imaging
features of PTLD have much in common with those of lymphoma related to acquired immunodeficiency
syndrome (AIDS), in that extranodal involvement was seen in more than 80% of AIDS-related
lymphoma, similar to the frequency of extranodal disease among PTLD patients.3,9 However,
CT manifestation of non-Hodgkin lymphoma in general population and PTLD in transplant
recipients have important difference that extranodal disease occurs only 25% of non-Hodgkin
lymphoma.3,5
CT findings of hepatic involvement of PTLD includes (in descending order of frequency
of occurrence) 1) discrete low-attenuation nodular lesions, ranging from 1 to 4 cm,
which has reduced enhancement compared with the normal liver parenchyma in the portal
venous phase (Fig. 1A and B), 2) ill-defined infiltrative or geographic pattern, which
has poorly-marginated but can be identified against a normally enhancing background
liver and can resemble focal fatty infiltration, 3) a heterogeneous mass at porta
hepatis, which can directly extend into the biliary tree or gallbladder, with resultant
hepatomegaly or biliary obstruction.3,9,11 On ultrasonography, these hepatic lesions
appear hypoechoic (Fig. 2) and they can be confused with liver abscesses on ultrasound.11,12
PTLD can involve other abdominal organs. Splenic involvement is less common, manifesting
as focal masses with or without splenomegaly.11,12 Imaging findings of hollow viscus
involvement also resemble those of lymphoma, although ulceration and perforation is
more common in PTLD.11,13 It presents with localized circumferential wall thickening,
aneurismal dilatation of involved loops, luminal excavation or ulceration, eccentric
polypoid mass, extrumural extention and intussusceptions.3 Extranodal involvement
of peritoneum and abdominal wall can produce diffuse soft-tissue infiltration or discrete
lobulated mass.3 The case presented above showed discrete multiple liver mass and
both types of peritoneal involvement (Fig. 1A-D). PTLD can affect both native and
transplanted kidneys and may manifest as focal renal masses or diffuse infiltration.3,5
In the cases of thoracic involvement, the most frequent imaging finding is nodules
with a peripheral and basal predominance. And other findings include air space consolidation,
mediastinal lymphadenopathy, pleural or chest wall masses, pericardial or pleural
effusions.5 Intracerebral PTLD is usually isolated and has similar imaging features
to AIDS-related cerebral lymphoma.5,14 The characteristic finding is of a cerebral
nodule demonstrating hemorrhage, necrosis and peripheral enhancement. Lesions are
most commonly seen in the periventricular and subcortical white matter. Biopsy may
be required to distinguish between PTLD and other disorders such as atypical infection.5
FDG-PET scanning proved superior efficacy compared with conventional CT scanning for
staging as well as treatment evaluation.1 PET scan can be an effective imaging method
for early detection and diagnosis of PTLD.
Treatment of PTLD always consists of reduction of immunosuppression. In addition,
monoclonal antibody therapy and antiviral therapies are frequently applied, and systemic
chemotherapy is applied in the case of non-response group. Distinguishing between
the polymorphic and monomorphic subtypes is important for treatment planning because
the former will often respond to immunomodulation alone, however this distinction
is not reliably made on the basis of imaging studies, tissue acquisition is necessary.
Tissue confirmation is also required to differentiate between PTLD and rejection.
SUMMARY
PTLD is a serious and still frequently observed complication of solid organ transplantation.
Liver is frequently involved organ, and well-defined multiple mass are most frequently
seen.